Solid earnings beat with broad-based growth in Oncology and Rare Disease offsets CVRM weakness. The CSPC obesity deal adds long-term pipeline optionality but near-term R&D spend will increase. Guidance reaffirmation supports current valuation. Watch for H1 2026 results on 27 July 2026 and upcoming Phase III readouts for Enhertu (DESTINY-Breast05) and Calquence (AMPLIFY).
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $185.00entry
- T+1 · 7mo ago +1.29%α +0.27% · $187.39
- T+5 · 7mo ago −0.10%α −3.21% · $184.81
- T+20 · 6mo ago +0.18%α −5.86% · $185.34
- T+60 · 4mo ago −9.04%α −12.78% · $168.27
Price Chart
How similar events traded
Executive Summary
AstraZeneca reported strong Q1 2026 results with Total Revenue up 8% CER to $15.3B, driven by Oncology (+16% CER) and Rare Disease (+15% CER). Core EPS grew 5% CER to $2.58, and FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth was reaffirmed. The company also closed a $1.2B upfront collaboration with CSPC for obesity/diabetes therapies and reported positive Phase III readouts for tozorakimab and efzimfotase alfa.
Key Facts
- Total Revenue $15,288M, up 8% CER (actual +13%)
- Reported EPS $1.99, up 8% CER; Core EPS $2.58, up 5% CER
- Oncology revenue +16% CER, Rare Disease +15% CER
- CVRM revenue declined 6% CER, primarily due to Farxiga generic competition
- FY 2026 guidance reaffirmed: mid-to-high single-digit revenue growth, low double-digit Core EPS growth
- Closed $1.2B upfront collaboration with CSPC for obesity/type 2 diabetes therapies
- Positive Phase III data for tozorakimab (COPD) and efzimfotase alfa (HPP); Enhertu patent litigation resolved favorably
- Net debt increased to $25.9B, driven by financing activities and business development payments
Financial Impact
Q1 2026 revenue $15.3B, operating profit $4.2B (reported) and $5.4B (core); Core EPS $2.58, up 5% CER; $1.2B upfront for CSPC deal and $100M for Jacobio
Risk Factors
- Generic competition pressuring CVRM revenue, especially Farxiga and Brilinta
- Increased leverage from $1.2B CSPC upfront and $1.99B new debt issuance
- Litigation overhang from 340B antitrust appeal and Texas qui tam trial scheduled for August 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index-headers.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047.txt | 0001654954-26-004047 |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers